Artwork

内容由i3 Health and I3 Health提供。所有播客内容(包括剧集、图形和播客描述)均由 i3 Health and I3 Health 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

What’s New With HER2: Charting New Paths in NSCLC Care Module 2 Podcast

18:34
 
分享
 

Manage episode 454112768 series 3456244
内容由i3 Health and I3 Health提供。所有播客内容(包括剧集、图形和播客描述)均由 i3 Health and I3 Health 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies. In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!
  continue reading

45集单集

Artwork
icon分享
 
Manage episode 454112768 series 3456244
内容由i3 Health and I3 Health提供。所有播客内容(包括剧集、图形和播客描述)均由 i3 Health and I3 Health 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies. In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!
  continue reading

45集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放